These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 19273826)

  • 41. Remote ischemic perconditioning in thrombolysed stroke patients: randomized study of activating endogenous neuroprotection - design and MRI measurements.
    Hougaard KD; Hjort N; Zeidler D; Sørensen L; Nørgaard A; Thomsen RB; Jonsdottir K; Mouridsen K; Hansen TM; Cho TH; Nielsen TT; Bøtker HE; Østergaard L; Andersen G
    Int J Stroke; 2013 Feb; 8(2):141-6. PubMed ID: 22463392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis.
    Thelengana A; Radhakrishnan DM; Prasad M; Kumar A; Prasad K
    Acta Neurol Belg; 2019 Sep; 119(3):359-367. PubMed ID: 29728903
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study.
    Campbell BC; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Yan B; Thijs V; Desmond PM; Parsons MW; Donnan GA; Davis SM
    Int J Stroke; 2020 Jul; 15(5):567-572. PubMed ID: 31564231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.
    Haley EC; Thompson JL; Grotta JC; Lyden PD; Hemmen TG; Brown DL; Fanale C; Libman R; Kwiatkowski TG; Llinas RH; Levine SR; Johnston KC; Buchsbaum R; Levy G; Levin B;
    Stroke; 2010 Apr; 41(4):707-11. PubMed ID: 20185783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparing mismatch strategies for patients being considered for ischemic stroke tenecteplase trials.
    Bivard A; Huang X; Levi CR; Campbell BC; Cheripelli BK; Chen C; Kalladka D; Moreton FC; Ford I; Davis SM; Donnan GA; Muir KW; Parsons MW
    Int J Stroke; 2020 Jul; 15(5):507-515. PubMed ID: 31684841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
    Saver JL; Goyal M; Bonafe A; Diener HC; Levy EI; Pereira VM; Albers GW; Cognard C; Cohen DJ; Hacke W; Jansen O; Jovin TG; Mattle HP; Nogueira RG; Siddiqui AH; Yavagal DR; Devlin TG; Lopes DK; Reddy V; du Mesnil de Rochemont R; Jahan R;
    Int J Stroke; 2015 Apr; 10(3):439-48. PubMed ID: 25777831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Complications of Intravenous Tenecteplase Versus Alteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Rose D; Cavalier A; Kam W; Cantrell S; Lusk J; Schrag M; Yaghi S; Stretz C; de Havenon A; Saldanha IJ; Wu TY; Ranta A; Barber PA; Marriott E; Feng W; Kosinski AS; Laskowitz D; Poli S; Mac Grory B
    Stroke; 2023 May; 54(5):1192-1204. PubMed ID: 36951049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of dosing errors between tenecteplase and alteplase for management of acute ischemic stroke.
    Ray B; Janzen KM; Curran M; Adamson R; Allen L; Warach S; Daley M
    J Am Pharm Assoc (2003); 2023; 63(2):643-647. PubMed ID: 36623954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol.
    Ribo M; Molina CA; Rovira A; Quintana M; Delgado P; Montaner J; Grivé E; Arenillas JF; Alvarez-Sabín J
    Stroke; 2005 Mar; 36(3):602-6. PubMed ID: 15692107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial.
    Zhu Z; Fu Y; Tian D; Sun N; Han W; Chang G; Dong Y; Xu X; Liu Q; Huang D; Shi FD
    Circulation; 2015 Sep; 132(12):1104-1112. PubMed ID: 26202811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic and prognostic value of early MR Imaging vessel signs in hyperacute stroke patients imaged <3 hours and treated with recombinant tissue plasminogen activator.
    Schellinger PD; Chalela JA; Kang DW; Latour LL; Warach S
    AJNR Am J Neuroradiol; 2005 Mar; 26(3):618-24. PubMed ID: 15764589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations.
    Hailu K; Cannon C; Hayes S
    Am J Health Syst Pharm; 2022 Jun; 79(12):944-949. PubMed ID: 35020806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making].
    Kakuda W; Abo M
    Brain Nerve; 2008 Oct; 60(10):1173-80. PubMed ID: 18975605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tenecteplase Treatment and Thrombus Characteristics Associated With Early Reperfusion: An EXTEND-IA TNK Trials Analysis.
    Yogendrakumar V; Churilov L; Guha P; Beharry J; Mitchell PJ; Kleinig TJ; Yassi N; Thijs V; Wu TY; Brown H; Dewey HM; Wijeratne T; Yan B; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM; Campbell BCV;
    Stroke; 2023 Mar; 54(3):706-714. PubMed ID: 36727510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Making a case for the right '-ase' in acute ischemic stroke: alteplase, tenecteplase, and reteplase.
    Chester KW; Corrigan M; Schoeffler JM; Shah M; Toy F; Purdon B; Dillon GM
    Expert Opin Drug Saf; 2019 Feb; 18(2):87-96. PubMed ID: 30712409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores.
    Lapchak PA; Song D; Wei J; Zivin JA
    Exp Neurol; 2004 Aug; 188(2):279-85. PubMed ID: 15246827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced Severity of Tissue Injury Within the Infarct May Partially Mediate the Benefit of Reperfusion in Ischemic Stroke.
    Ng FC; Churilov L; Yassi N; Kleinig TJ; Thijs V; Wu TY; Shah DG; Dewey HM; Sharma G; Desmond PM; Yan B; Parsons MW; Donnan GA; Davis SM; Mitchell PJ; Leigh R; Campbell BCV;
    Stroke; 2022 Jun; 53(6):1915-1923. PubMed ID: 35135319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials.
    Burgos AM; Saver JL
    Stroke; 2019 Aug; 50(8):2156-2162. PubMed ID: 31318627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tenecteplase in acute ischemic stroke: Review of the literature and expert consensus from the French Neurovascular Society.
    Olindo S; Albucher JF; Bejot Y; Berge J; Cordonnier C; Guillon B; Sablot D; Tardy J; Alamowitch S; Sibon I
    Rev Neurol (Paris); 2023 Mar; 179(3):150-160. PubMed ID: 36369068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.